These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 2357772)

  • 1. Phase I study of mitozolomide on a once daily for 5 days schedule.
    Schornagel JH; Simonetti G; Dubbelman R; ten Bokkel Huinink WW; McVie JG
    Cancer Chemother Pharmacol; 1990; 26(3):237-8. PubMed ID: 2357772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I clinical trial of mitozolomide.
    Newlands ES; Blackledge G; Slack JA; Goddard C; Brindley CJ; Holden L; Stevens MF
    Cancer Treat Rep; 1985; 69(7-8):801-5. PubMed ID: 4016790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase I study of bendamustine hydrochloride administered once every 3 weeks in patients with solid tumors.
    Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
    Anticancer Drugs; 2007 Jun; 18(5):587-95. PubMed ID: 17414628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of mitozolomide (M & B 39,565) in head and neck cancer.
    Herait P; Armand JP; Benahmed M; Domenge C; Fontana X; Recondo G; Cvitkovic E; Delgado FM
    Med Oncol Tumor Pharmacother; 1989; 6(4):267-9. PubMed ID: 2615530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II studies of mitozolomide in melanoma, lung and ovarian cancer.
    Harding M; Docherty V; Mackie R; Dorward A; Kaye S
    Eur J Cancer Clin Oncol; 1989 May; 25(5):785-8. PubMed ID: 2544429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of mitozolomide (M & B 39,565) in colorectal and breast cancer.
    Herait P; Rougier P; Oliveira J; Delgado FM; May-Levin F; Hayat M; Armand JP
    Invest New Drugs; 1988 Dec; 6(4):323-5. PubMed ID: 3229944
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral topotecan given once or twice daily for ten days: a phase I pharmacology study in adult patients with solid tumors.
    Gerrits CJ; Burris H; Schellens JH; Eckardt JR; Planting AS; van der Burg ME; Rodriguez GI; Loos WJ; van Beurden V; Hudson I; Fields S; Von Hoff DD; Verweij J
    Clin Cancer Res; 1998 May; 4(5):1153-8. PubMed ID: 9607572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A clinical and pharmacological study of high-dose mitozolomide given in conjunction with autologous bone marrow rescue.
    McKeage M; Dady P; Clear M; MacDonald A
    Cancer Chemother Pharmacol; 1992; 29(3):201-6. PubMed ID: 1733552
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of mitozolomide in patients with advanced ovarian cancer. A study of the EORTC Gynecological Cancer Cooperative Group.
    Neijt JP; van der Burg ME; Guastalla JP; George M; Piccart M; Vermorken J; Carnino F; Rotmensz N
    Acta Oncol; 1989; 28(5):663-5. PubMed ID: 2590542
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.
    Brown TD; Ettinger DS; Donehower RC
    J Clin Oncol; 1986 Aug; 4(8):1270-6. PubMed ID: 3525770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of bendamustine hydrochloride administered day 1+2 every 3 weeks in patients with solid tumours.
    Rasschaert M; Schrijvers D; Van den Brande J; Dyck J; Bosmans J; Merkle K; Vermorken JB
    Br J Cancer; 2007 Jun; 96(11):1692-8. PubMed ID: 17486132
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tallimustine, an effective antileukemic agent in a severe combined immunodeficient mouse model of adult myelogenous leukemia, induces remissions in a phase I study.
    Beran M; Jeha S; O'Brien S; Estey E; Vitek L; Zurlo MG; Rios MB; Keating M; Kantarjian H
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2377-84. PubMed ID: 9815637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of mitozolomide in advanced soft tissue sarcoma of adults: the EORTC Soft Tissue and Bone Sarcoma Group.
    Somers R; Santoro A; Verweij J; Lucas P; Rouëssé J; Kok T; Casali A; Seynaeve C; Thomas D
    Eur J Cancer; 1992; 28A(4-5):855-7. PubMed ID: 1524907
    [No Abstract]   [Full Text] [Related]  

  • 14. Mitozolomide in advanced renal cancer. A phase II study in previously untreated patients from the EORTC Genito-Urinary Tract Cancer Cooperative Group.
    van Oosterom AT; Stoter G; Bono AV; Splinter TA; Fossa SD; Verbaeys AJ; de Mulder PH; de Pauw M; Sylvester R
    Eur J Cancer Clin Oncol; 1989 Aug; 25(8):1249-50. PubMed ID: 2767112
    [No Abstract]   [Full Text] [Related]  

  • 15. Relationship between the pharmacokinetics and toxicity of mitozolomide.
    Kerr DJ; Slack JA; Secrett P; Stevens MF; Blackledge GR; Bradley C; Kaye SB
    Cancer Chemother Pharmacol; 1990; 25(5):352-4. PubMed ID: 2306796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase I and pharmacokinetic study of tallimustine [PNU 152241 (FCE 24517)] in patients with advanced cancer.
    Weiss GR; Poggesi I; Rocchetti M; DeMaria D; Mooneyham T; Reilly D; Vitek LV; Whaley F; Patricia E; Von Hoff DD; O'Dwyer P
    Clin Cancer Res; 1998 Jan; 4(1):53-9. PubMed ID: 9516952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The clinical phase I study of TNP-351. The TNP-351 Research Committee].
    Taguchi T; Niitani H; Furue H; Tsukagoshi S; Kanamaru R; Hasegawa K; Akazawa S; Yoneda S; Tominaga T; Sasaki T
    Gan To Kagaku Ryoho; 1995 Feb; 22(2):259-71. PubMed ID: 7857102
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I trial of trimetrexate glucuronate (NSC 352122) given every 3 weeks: clinical pharmacology and pharmacodynamics.
    Grochow LB; Noe DA; Ettinger DS; Donehower RC
    Cancer Chemother Pharmacol; 1989; 24(5):314-20. PubMed ID: 2758561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abbreviated phase I clinical trial of i.v. mitozolomide.
    Joss RA; Ryssel HJ; Bischoff AK; Goldhirsch A; Brunner KW
    Cancer Treat Rep; 1986 Jun; 70(6):797-8. PubMed ID: 3524827
    [No Abstract]   [Full Text] [Related]  

  • 20. A phase I and pharmacological study of protracted infusions of crisnatol mesylate in patients with solid malignancies.
    Villalona-Calero MA; Petit T; Kuhn J; Cobb P; Kraynak M; Eckhardt SG; Drengler R; Simmons C; Santabarbara P; Von Hoff DD; Rowinsky EK
    Clin Cancer Res; 1999 Nov; 5(11):3369-78. PubMed ID: 10589747
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.